Reference SummaryKwak MK, PLoS One 2013;8(1):e53476
Title |
Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. | ||||||||||||||
Authors |
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z | ||||||||||||||
Journal |
PLoS One | ||||||||||||||
Volume |
8 | ||||||||||||||
Issue |
1 | ||||||||||||||
Year |
2013 | ||||||||||||||
Pages |
e53476 | ||||||||||||||
Abstract |
The PTEN tumor suppressor gene is frequently inactivated in human prostate cancer. Using Osr1 (odd skipped related 1)-Cre mice, we generated a novel conditional Pten knockout mouse strain, Pten(LoxP):Osr1-Cre. Conditional biallelic and monoallelic Pten knockout mice were viable. Deletion of Pten expression was detected in the prostate of Pten(LoxP/LoxP):Osr1-Cre mice as early as 2 weeks of age. Intriguingly, Pten(LoxP/LoxP):Osr1-Cre mice develop high-grade prostatic intraepithelial neoplasms (PINs) with high penetrance as early as one-month of age, and locally invasive prostatic tumors after 12-months of age. Pten(LoxP/+):Osr1-Cre mice show only mild oncogenic changes after 8-weeks of age. Castration of Pten(LoxP/LoxP):Osr1-Cre mice shows no significant regression of prostate tumors, although a shift of androgen receptor (AR) staining from the nuclei to cytoplasm is observed in Pten null tumor cells of castrated mice. Enhanced Akt activity is observed in Pten null tumor cells of castrated Pten(LoxP/LoxP):Osr1-Cre. This study provides a novel mouse model that can be used to investigate a primary role of Pten in initiating oncogenic transformation in the prostate and to examine other genetic and epigenetic changes that are required for tumor progression in the mouse prostate. | ||||||||||||||
Links |
J:195810 – MGI References 23308230 – National Library of Medicine/PubMed |
||||||||||||||
Strain Notes
|
Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
---|---|---|---|---|---|
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Lung carcinoma | Lung |
3.7 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Mammary gland adenocarcinoma | Mammary gland |
9.4 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Mesodermal cell/mesoblast sarcoma | Gastrointestinal tract |
6.25 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | PNS - Nerve sheath tumor - malignant | PNS - Nerve sheath |
3.7 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland - Anterior lobe prostatic intraepithelial neoplasia - high grade (HGPIN) | Prostate gland - Anterior lobe |
100 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland - Dorsolateral lobe prostatic intraepithelial neoplasia - high grade (HGPIN) | Prostate gland - Dorsolateral lobe |
100 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland - Ventral lobe prostatic intraepithelial neoplasia - high grade (HGPIN) | Prostate gland - Ventral lobe |
100 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland adenocarcinoma - well-differentiated | Prostate gland |
12.5 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland carcinoma | Prostate gland |
62.5 |
||
B6.Cg-Ptentm1Hwu/+ Tg(Osr1-cre)4Mrt | Prostate gland carcinoma | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu | Prostate gland carcinoma | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu/+ | Prostate gland carcinoma | Prostate gland |
0 |
||
B6.Cg | Prostate gland carcinoma | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland carcinoma - solid | Prostate gland |
50 |
||
B6.Cg-Ptentm1Hwu/+ Tg(Osr1-cre)4Mrt | Prostate gland hyperplasia | Prostate gland |
25 |
||
B6.Cg-Ptentm1Hwu | Prostate gland hyperplasia | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu/+ | Prostate gland hyperplasia | Prostate gland |
0 |
||
B6.Cg | Prostate gland hyperplasia | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland lesion | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu/+ Tg(Osr1-cre)4Mrt | Prostate gland lesion | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu/+ Tg(Osr1-cre)4Mrt | Prostate gland prostatic intraepithelial neoplasia (PIN) | Prostate gland |
29 - 87.5 |
||
B6.Cg-Ptentm1Hwu | Prostate gland prostatic intraepithelial neoplasia (PIN) | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu/+ | Prostate gland prostatic intraepithelial neoplasia (PIN) | Prostate gland |
0 |
||
B6.Cg | Prostate gland prostatic intraepithelial neoplasia (PIN) | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland prostatic intraepithelial neoplasia - high grade (HGPIN) | Prostate gland |
100 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland prostatic intraepithelial neoplasia - high grade (HGPIN) |
|
Prostate gland |
100 |
|
B6.Cg-Ptentm1Hwu/+ Tg(Osr1-cre)4Mrt | Prostate gland prostatic intraepithelial neoplasia - high grade (HGPIN) | Prostate gland |
37.5 - 62.5 |
||
B6.Cg-Ptentm1Hwu Tg(Pbsn-cre)4Prb | Prostate gland prostatic intraepithelial neoplasia - high grade (HGPIN) | Prostate gland |
observed |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland tumor | Prostate gland |
0 |
||
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | Prostate gland tumor |
|
Prostate gland |
observed |
|
B6.Cg-Ptentm1Hwu Tg(Osr1-cre)4Mrt | (Unspecified organ) cystadenoma - papillary | (Unspecified organ) |
3.7 |